ORTHOBOND

Orthobond Corp. develops surface modification technology that can be applied to synthetic materials to produce biological responses. It offers a technology based on self-assembled monolayers of phosphonate (SAMP); and osteoconductive self-assembled monolayer of phosphonate surface modification that elicits a biological response on inorganic implants without the use of a biologic. The company also provides bioresistant technology to address the need of tissue integration into permanent implants; and AI-SAMP anti-infective technology that helps in preventing a range of orthopedic infections by killing bacteria as they contact the pin surface and preventing biofilm formation, pre and post-operatively. Orthobond Corp. was founded in 2003 and is based in North Brunswick, New Jersey.